In brief
JBS and Viva signed the definitive JBS Viva agreement, a leather joint venture with 50% for each partner.
JBS contributes its Brazilian leather assets and raw hides from its plants, and Viva contributes operations and chemicals; closing depends on conditions precedent.
What we know
04Verified fact · material
JBS contributes its leather production assets in Brazil and international subsidiaries and will supply raw hides from its plants, while Viva contributes its leather operations and the manufacture of tanning chemicals; the Cactus (Texas), Germany, Uruguay and Mexico units and the collagen and gelatin operations stay out, per CNN Brasil and Exame.
Perimeter of the deal.
Verified fact
The board will have six seats, three per partner, with JBS naming the chair and CFO and Viva the CEO and operations director; JBS will keep supplying raw hides and will receive trimmings for gelatin and collagen production, per CNN Brasil.
Governance and contracts, one source.
Sources[01]
Transmission to assets
Market read-through
For JBS, the joint venture cuts exposure to a cyclical business and frees capital, without losing hide supply and trimmings for collagen.
The agreement still depends on conditions precedent and antitrust approval, which delays the accounting effect.
Portfolio impact
01Exiting a low-margin business simplifies the portfolio and frees capital.
Marginally positive in the medium term.
What would change the view: Depends on closing and the value of contributed assets.
Direction is an explanatory hypothesis, not a forecast or recommendation.
Next signals
What to watch
- Material fact at CVM and the SEC with contributed asset values.
- Cade and foreign approvals.
- Closing date and the effect on 4Q26 accounts.
Limits of the reporting
What remains uncertain
- No source reports revenue, plant count or value of contributed assets.
- CNN does not say whether a material fact was filed; Seu Dinheiro cites the company statement.